Prospects diverge for 2 experimental drugs
Prospects for two experimental drugs important to Massachusetts biotechnology companies diverged Monday, with one moving forward and the other facing a delay. ImmunoGen Inc. of Waltham said its partner, the Genentech division of Swiss drug maker Roche AG, has applied to the Food and Drug Administration for approval of a promising breast cancer drug using ImmunoGen’s technology. If the agency grants accelerated approval for the drug, it could be on the market by early next year. At the same time, the launch of Lemtrada, a high-profile multiple sclerosis treatment that Genzyme had hoped to make available by early next year, is likely to be postponed.